All News

On the glut of patenting, BASF's rising research budget, football fever in the Commons, and other insights into R&D management

"Scientific work … must be done for itself, for the beauty of science." Marie Curie, chemist & physicist (1867 - 1934)

New regulations on the registration and testing of chemicals could have some problematic knock-on effects on European R&D – but they could also bring some lucrative work the way of contract research organisations.

Some strange new ways of raising money are starting to emerge - but would-be borrowers and lenders are still making sense of them.

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?

A new proposal from the European Investment Fund seeks to accelerate the success of European technology transfer projects. A noble idea, says Mary Lisbeth D'Amico in her fortnightly column, but no one has yet stepped up to foot the bill.

OrthoMimetics, the first technology spin-out from the Cambridge-MIT Institute, Cambridge, UK, has begun its search for initial funding.

Venture capital’s refusal to continue support helped Cyan Technology into liquidation. Rebuilt by its management, Cyan is now wary of asking VCs for money.

A politician's gaffe highlights the gender gap in science. Political action, not talk, is what's needed to close it.

Scientists are moving around as never before. And, argues Jean Guinet from the OECD, that’s not necessarily a bad thing.

Better, brighter, faster – that's where photonic lasers are trying to take us. A lay guide to the technology.

A British start-up is betting it has a better way for television networks to watch their viewers watching them.

With licensing and collaboration now the lifeblood of the drug industry, the annual BIO-Europe get-together was focused on partnering. Nuala Moran was there.